JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us

Subphenotypes of Long COVID and the clinical applications of probiotics

  • 0Sunway Microbiome Centre, School of Medical and Life Sciences, Sunway University, Petaling Jaya, Selangor 47500, Malaysia.
Pharmacotherapy +

|

January 25, 2025

|

January 25, 2025

View abstract on PubMed

Summary

This summary is machine-generated.

Long COVID, a condition following SARS-CoV-2 infection, is linked to gut microbiota dysbiosis and inflammation. Probiotics show promise in restoring gut balance and alleviating Long COVID symptoms by modulating the immune response.

Area Of Science

  • Microbiology
  • Immunology
  • Infectious Diseases

Background

  • Coronavirus disease (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), presents long-term health impacts beyond acute infection.
  • Post-acute sequelae of COVID-19 (PASC), or Long COVID, involves diverse symptoms across multiple organ systems, including cardiac, renal, respiratory, musculoskeletal, and nervous conditions.
  • Long COVID is characterized by prolonged inflammation and immune system dysfunction.

Purpose Of The Study

  • To review distinct subphenotypes of Long COVID.
  • To identify microbiota dysbiosis as a common theme and potential therapeutic target in Long COVID.
  • To evaluate the clinical development of probiotics for Long COVID symptom mitigation.

Main Methods

  • Literature review of Long COVID subphenotypes.
  • Analysis of the association between microbiota dysbiosis and Long COVID.
  • Evaluation of current research on probiotic interventions for Long COVID.

Main Results

  • Microbiota dysbiosis is a prevalent feature across Long COVID subphenotypes.
  • Long COVID is associated with persistent inflammation, potentially driven by immune dysregulation.
  • Probiotics may offer a therapeutic strategy by rebalancing gut microbiota and modulating immune responses.

Conclusions

  • Restoring gut microbiota balance through probiotics is a promising avenue for Long COVID treatment.
  • Further research is needed to understand specific bacterial strain modulation and its association with Long COVID symptoms.
  • Effective probiotic formulations could provide reliable therapies for managing Long COVID.

Keywords:

Related Concept Videos

Chronic Bowel Disorders: Introduction 01:17

385

Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...

COPD: Pathogenesis and Clinical Features 01:20

228

Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...

Chronic Pharyngitis 01:23

1.0K

Chronic pharyngitis refers to persistent inflammation of the pharyngial mucosa.
Etiology
It often arises from persistent viral or bacterial infections affecting sinuses and tonsils.
Additional contributing factors include inadequate dental hygiene, mouth breathing, recurring tonsillitis, allergic rhinitis, laryngopharyngeal reflux, and exposure to smoke, chemicals, and other environmental pollutants. Allergic reactions to pollen, mold, and pet dander, chronic cough, excessive voice usage,...

Drugs for Treatment of Constipation-Predominant IBS 01:21

131

Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...